These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 23231890)
1. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G BMC Pulm Med; 2012 Dec; 12():75. PubMed ID: 23231890 [TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882 [TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. Copher R; Cerulli A; Watkins A; Laura Monsalvo M J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140 [TBL] [Abstract][Full Text] [Related]
5. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. Vida VL; Gaitan G; Quezada E; Barnoya J; Castañeda AR Cardiol Young; 2007 Feb; 17(1):72-7. PubMed ID: 17184573 [TBL] [Abstract][Full Text] [Related]
6. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Ramani GV; Park MH Drug Des Devel Ther; 2010 May; 4():61-70. PubMed ID: 20531962 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Wang RC; Jiang FM; Zheng QL; Li CT; Peng XY; He CY; Luo J; Liang ZA Respir Med; 2014 Mar; 108(3):531-7. PubMed ID: 24462476 [TBL] [Abstract][Full Text] [Related]
9. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Dranitsaris G; Mehta S Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194 [TBL] [Abstract][Full Text] [Related]
10. Sildenafil: a review of its use in pulmonary arterial hypertension. Croom KF; Curran MP Drugs; 2008; 68(3):383-97. PubMed ID: 18257613 [TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260 [TBL] [Abstract][Full Text] [Related]
12. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Martin AL; Huelin R; Wilson D; Foster TS; Mould JF J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555 [TBL] [Abstract][Full Text] [Related]
13. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. Sikirica M; Iorga SR; Bancroft T; Potash J BMC Health Serv Res; 2014 Dec; 14():676. PubMed ID: 25539602 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Xu XQ; Jing ZC; Zhang JH; Wu Y; Wang Y; Jiang X; Wang ZX; Sun YG; Pu JL; Yang YJ Hypertens Res; 2009 Oct; 32(10):911-5. PubMed ID: 19644505 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG; Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ; Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
18. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. Shlobin OA; Brown AW; Weir N; Ahmad S; Lemma M; Nathan SD Lung; 2012 Oct; 190(5):573-8. PubMed ID: 22797830 [TBL] [Abstract][Full Text] [Related]
19. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239 [TBL] [Abstract][Full Text] [Related]
20. Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. Burger CD; Pruett JA; Lickert CA; Berger A; Murphy B; Drake W J Manag Care Spec Pharm; 2018 Mar; 24(3):291-302. PubMed ID: 29406840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]